⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Julian MaressaD.O.

Family Practice · Berlin, NJ 08009

NPI: 1275643116

Share:

45

🟠 Elevated

🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)

Exclusion type: 1128(b)(4) — License Revocation/Suspension · Date: 12/18/2025 · State: NJ

Risk Flags

High opioid rate vs specialty peersElevated antipsychotic prescribing (65+)Opioid + benzodiazepine co-prescriberOIG Excluded Provider

Risk indicators are statistical patterns, not allegations. Learn more

3,540

Total Claims

$335K

Drug Cost

228

Beneficiaries

$1,471

Cost/Patient

Risk Score Breakdown 45/100

Low (0)Moderate (15)Elevated (30)High (50+)
OIG excluded provider+20
Opioid rate vs specialty peers+10
Opioid + benzodiazepine combo+8
Elderly antipsychotic prescribing+5

Score components are additive. Read full methodology

Peer Comparison vs. 106,889 Family Practice providers

+450%

Opioid rate vs peers

14.2% vs 2.6% avg

+38%

Cost per patient vs peers

$1,471 vs $1,068 avg

-1%

Brand preference vs peers

8.9% vs 9.0% avg

⚠️ Opioid + Benzodiazepine Co-Prescriber

This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.

🔎 Data Overview

🚫

This provider appears on the federal OIG exclusion list, meaning they have been formally barred from participating in federal healthcare programs due to fraud, patient abuse, licensing issues, or other misconduct. The fact that they still appear in active prescribing data is a significant concern.

💊

Opioid rate is 450% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.

⚠️

This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

14.2%

Opioid Rate

502

Opioid Claims

$46K

Opioid Cost

5.4%

Long-Acting Rate

Brand vs Generic

91% generic

Brand: 312 claims · $239K

Generic: 3,204 claims · $95K

Top Prescribed Drugs

Drug (Generic)ClaimsCost
Brexpiprazole18$52K
Apixaban25$28K
Oxycodone Hcl24$21K
Empagliflozin22$19K
Dapagliflozin Propanediol16$14K
Vortioxetine Hydrobromide17$13K
Fluticasone/Umeclidin/Vilanter14$11K
Hydrocodone/Ibuprofen25$7,864
Oxycodone Hcl201$7,811
Alprazolam271$4,793
Hydromorphone Hcl76$3,546
Lidocaine13$3,517
Hydrocodone/Acetaminophen81$3,430
Butorphanol Tartrate13$2,783
Dextroamphetamine/Amphetamine42$2,449

Prescribing Profile

80

Unique Drugs

$61K

IRA Negotiated Drugs

45.0

Anomaly Score

Patient Profile

72

Avg Age

56%

Female

1.13

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data